Poly Medicure Intrinsic Value
Poly Medicure (POLYMED) median intrinsic value is ₹751.37 from 9 valuation models (range ₹454–₹1176), vs current price ₹1512.10 — -50.3% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit POLYMED stock overview.
POLYMED Valuation Methods Summary — DCF, Graham Number & P/E
Poly Medicure intrinsic value across 9 models vs current price ₹1512.10 — upside/downside and value range per method. Also explore POLYMED price trends to track price trends across different timeframes.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹797.28 | ₹637.82 - ₹956.74 | -47.3% | EPS: ₹36.24, Sector P/E: 22x |
| Book Value Method | asset | ₹1084.71 | ₹976.24 - ₹1193.18 | -28.3% | Book Value/Share: ₹542.35, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹751.37 | ₹676.23 - ₹826.51 | -50.3% | Revenue/Share: ₹375.69, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1176.47 | ₹1058.82 - ₹1294.12 | -22.2% | EBITDA: ₹600.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹639.22 | ₹511.38 - ₹767.06 | -57.7% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹453.63 | ₹408.27 - ₹498.99 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹559.91 | ₹503.92 - ₹615.90 | -63.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹865.88 | ₹779.29 - ₹952.47 | -42.7% | ROE: 13.3%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹665.01 | ₹598.51 - ₹731.51 | -56.0% | EPS: ₹36.24, BVPS: ₹542.35 |
POLYMED Intrinsic Value vs Market Price — All Valuation Models
Poly Medicure fair value range ₹454–₹1176 vs current market price ₹1512.10 across 9 valuation models. Read POLYMED dividend growth for the complete payout history and dividend yield track record.
POLYMED Intrinsic Value Analysis — Undervalued or Overvalued?
Poly Medicure median intrinsic value ₹751.37, current price ₹1512.10 — Trading Above Calculated Value by 50.3%, margin of safety -100.0%.
What is the intrinsic value of POLYMED?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Poly Medicure (POLYMED) is ₹751.37 (median value). With the current market price of ₹1512.10, this represents a -50.3% variance from our estimated fair value.
The valuation range spans from ₹453.63 to ₹1176.47, indicating ₹453.63 - ₹1176.47.
Is POLYMED undervalued or overvalued?
Based on our multi-method analysis, Poly Medicure (POLYMED) appears to be trading above calculated value by approximately 50.3%.
POLYMED Financial Health — Key Ratios vs Industry Benchmarks
Poly Medicure financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 33.63 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 13.3% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 26.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.60x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
POLYMED Cash Flow Quality — Operating & Free Cash Flow
Poly Medicure operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹240 Cr | ₹-357 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹266 Cr | ₹146 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹191 Cr | ₹102 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹124 Cr | ₹82 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹119 Cr | ₹-99 Cr | Positive Operating Cash Flow | 6/10 |